1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development through the characterization of the natural history of rare diseases/conditions with unmet needs. Through the support of efficient and innovative natural history studies, FDA expects to address critical knowledge gaps, to remove major barrier(s) to progress in the field, to exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and to inform current or future product development including the design of clinical trial(s) and to ultimately inform the development of medical products that meet patient needs.
Funding Opportunity Number: RFA-FD-19-001. Assistance Listing: 93.103. Funding Instrument: G. Category: HL.
Get alerted about grants like this
Save a search for “Food and Drug Administration” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Eligible applicants: State governments; County governments; City or township governments; Special district governments; Independent school districts; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Native American tribal organizations (other than Federally recognized); Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Private institutions of higher education; For-profit organizations other than small businesses; Small businesses. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is January 10, 2019. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP) is announcing its intent to accept and consider a single source application for the award of a grant to the Duke Universitys Duke Translational Medicine Institute (DTMI) to support increasing the quality and efficiency of clinical trials. Funding Opportunity Number: RFA-FD-14-017. Assistance Listing: 93.103. Funding Instrument: G. Category: FN,HL. Award Amount: Up to $7.5M per award.
The Center for Drug Evaluation and Research (CDER) receives a vast and growing amount of data in a variety of regulatory submissions from a multitude of sources and in a variety of formats. This wealth of data holds great potential to advance CDER’s regulatory and scientific work, but the present lack of standardized data creates significant challenges to realizing that potential.The volume and complexity of drug-related information submitted to CDER for regulatory review is creating significant challenges to the Center’s ability to efficiently and effectively perform its critical public health mission.The lack of standardized data affects CDER’s review processes by curtailing a reviewer’s ability to perform integral tasks such as rapid acquisition, analysis, storage and reporting of regulatory data. Improved data quality, accessibility and predictability will give reviewers more time to carry out complex analyses, ask in-depth questions and address late-emerging issues. Standardized data will allow reviewers to increase review consistency and perform evaluations across the drug lifecycle. This will enhance the Center’s performance across key drug regulatory functions and ongoing business operations, including pre-market review, post-market safety, oversight of drug quality, and oversight of drug promotion.In accordance with the Office of Management and Budget (OMB) Circular A-119, the FDA will: use voluntary, consensus-based standards development processes in place of government unique standards unless such standards are inconsistent with law or otherwise impractical; advocate to align these standards with existing health information technology initiatives, laws, regulations, and mandates; and promote coordination with other standards currently in use. The projects selected under this funding opportunity must adhere to these principles. Funding Opportunity Number: RFA-FD-15-033. Assistance Listing: 93.103. Funding Instrument: CA. Category: FN,IS. Award Amount: $50K – $225K per award.
The Food and Drug Administration (FDA), Center for Food Safety and Applied Nutrition (CFSAN), Office of Food Safety (OFS) is announcing its intent to award a single source cooperative agreement to the Interstate Shellfish Sanitation Conference (ISSC). The purpose of this cooperative agreement is to enhance the FDA’s molluscan shellfish sanitation program and provide the public greater assurance of the quality and safety of these products. Molluscan shellfish have been recognized by FDA as a significant source of seafood-borne illnesses and continue to be the subject of congressional, state, industry, and public concern. FDA has given high priority to enhance the agency's shellfish safety program and to provide the public greater assurance of the quality and safety of these products. FDA administers the National Shellfish Sanitation Program (NSSP). Under that program, the NSSP Model Ordinance serves as guidance for State shellfish sanitation programs and the promulgation of state regulations and laws concerning shellfish safety. This cooperative agreement will enhance FDA efforts to help ensure that shellfish are free of harmful pathogens. Funding Opportunity Number: RFA-FD-16-006. Assistance Listing: 93.103. Funding Instrument: CA. Category: AG,CP,FN. Award Amount: Up to $500K per award.
The Bureau of Reclamation, Upper Colorado Region has generated collections of archeological and historical objects and records through its various works. Following 36 CFR 79, federal collections shall be curated by a repository meeting the Department of the Interior or the American Association of Museums standards. The NHMU meets these standards. The NHMU hired by the Secretary of the Interior (National Park Service) to generate the collections before the Colorado River Storage Project dams were built in the 1950s and 1960s. The collections were deposited with NHMU in the 1950s, and under the terms of the original agreements between the United States (National Park Service) and the MNA, they were stipulated to “retain” the collection in perpetuity. Funding Opportunity Number: BOR-UC-16-N001. Assistance Listing: 15.511. Funding Instrument: G. Category: HU. Award Amount: $1 – $200K per award.
This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field.In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder. Funding Opportunity Number: PAR-16-061. Assistance Listing: 93.847,93.865. Funding Instrument: G. Category: FN,HL,ISS.